Gene therapy of cancer: translational approaches from preclinical studies to clinical implementation
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
San Diego [u.a.]
Acad. Press
2002
|
| Ausgabe: | 2. ed. |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | Includes bibliographical references and index |
| Beschreibung: | XIX, 534 S. Ill., graph. Darst. |
| ISBN: | 0124375510 |
Internformat
MARC
| LEADER | 00000nam a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV014485114 | ||
| 003 | DE-604 | ||
| 005 | 20030703 | ||
| 007 | t | ||
| 008 | 020603s2002 xxuad|| |||| 00||| eng d | ||
| 010 | |a 2001099437 | ||
| 020 | |a 0124375510 |9 0-12-437551-0 | ||
| 035 | |a (OCoLC)49664744 | ||
| 035 | |a (DE-599)BVBBV014485114 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 044 | |a xxu |c US | ||
| 049 | |a DE-355 | ||
| 050 | 0 | |a RC271.G45 | |
| 082 | 0 | |a 616.99/4042 |2 21 | |
| 084 | |a XH 3500 |0 (DE-625)152892:12905 |2 rvk | ||
| 245 | 1 | 0 | |a Gene therapy of cancer |b translational approaches from preclinical studies to clinical implementation |c ed. by Edmund C. Lattime ... |
| 250 | |a 2. ed. | ||
| 264 | 1 | |a San Diego [u.a.] |b Acad. Press |c 2002 | |
| 300 | |a XIX, 534 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 500 | |a Includes bibliographical references and index | ||
| 650 | 4 | |a Cancer - Immunothérapie | |
| 650 | 4 | |a Cancer - Thérapie génique | |
| 650 | 4 | |a Cancer |x Gene therapy | |
| 650 | 4 | |a Cancer |x Immunotherapy | |
| 650 | 4 | |a Gene Therapy |x methods | |
| 650 | 4 | |a Immunotherapy |x methods | |
| 650 | 4 | |a Neoplasms |x genetics | |
| 650 | 4 | |a Neoplasms |x therapy | |
| 650 | 4 | |a Protein Biosynthesis | |
| 650 | 0 | 7 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Gentherapie |0 (DE-588)4296957-8 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 0 | 1 | |a Gentherapie |0 (DE-588)4296957-8 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Lattime, Edmund C. |e Sonstige |4 oth | |
| 700 | 1 | |a Gerson, Stanton L. |e Sonstige |4 oth | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=009879472&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-009879472 | ||
Datensatz im Suchindex
| _version_ | 1804129305201999872 |
|---|---|
| adam_text | Contributors xv
Preface xix
PART
i
VECTORS FOR GENE THERAPY
OF CANCER
1. Retroviral Vector Design for Cancer
Gene Therapy
CHRISTOPHER BAUM, WOLFRAM OSTERTAG,
CAROL STOCKING. AND DOROTHEE VON LAER
I. Introduction 3
II. Applications for Retroviral Vectors in Oncology 4
III. Biology of Retroviruses 6
IV. Principles of Retroviral Vector Systems 9
V. Advances in Retroviral Vector Tailoring II
VI. Outlook 22
References 23
2. Noninfectious Gene Transfer
and Expression Systems for Cancer
Gene Therapy
MARK |. COOPER
I. Introduction 31
II. Advantages and Disadvantages of Infectious.
Viral Based Vectors for Human Gene Therapy 31
III. Rationale for Considering Noninfectious.
Plasmid Based Expression Systems 33
IV. Gene Transfer Technologies for Plasmid Based Vectors:
Prcclinical Models and Clinical Cancer Gene Therapy
Trials 33
V. Plasmid Expression Vectors 37
VI. Future Directions 43
References 45
3. Parvovirus Vectors for the Gene
Therapy of Cancer
K. K. WONG. |R. AND SASWATI CHATTER|EE
I. Introduction 53
II. Biology of Parvoviridae and Vector Development 54
III. Applications of Recombinanl Parvovirus Vectors to
Cancer Gene Therapy 61
IV. Perspectives. Problems, and Future Considerations 71
References 71
4. Antibody Targeted Gene Therapy
C. LAMPERT, A. M. McCALL. AND L. M. WEINER
I. Introduction 81
II. Background: Monoclonal Antibodies and
Cancer Therapy XI
III. Recent Advances: Monoclonal Antibody Mediated
Targeting and Cancer Gene Therapy H4
IV. Future Directions 91
References 92
5. Ribozymes in Cancer
Gene Therapy
CARMELA BEGER. MARTIN KRUGER.
AND FLOSSIE WONG STAAL
I. Introduction 95
II. Ribozyme Structures and Functions 96
III. Cancer Disease Models for Ribozyme Application 98
IV. Challenges and Future Directions 102
References 103
6. The Advent of Lentiviral
Vectors: Prospects for
Cancer Therapy
MICHEL SADELAIN AND ISABELLE RIVIERE
I. Introduction 109
II. Structure and Function of Lentiviruses 110
III. Features that Distinguish Lentiviral from
Oncoretroviral Vectors 111
IV. Manufacture of Lentiviral Vectors 113
V. Possible Applications of Lentiviral Vectors in
Cancer Therapy 117
VI. Conclusions 119
References 120
PART
n
IMMUNE TARGETED
GENE THERAPY
7. Immunologic Targets for
the Gene Therapy
of Cancer
SUZANNE OSTRAND ROSENBERG, VIRGINIA K. CLEMENTS,
SAMUDRA DISSANAYAKE, MILEKA GILBERT,
BETH A. PULASKI, AND LING OJ
I. Introduction 128
II. Cellular (T Lymphocyte Mediated) Versus Humoral
(Antibody Mediated) Immune Responses to Tumor
Cells 128
III. Response of CD4+ and CD8+ T Lymphocytes to Tumor
Antigens Presented in the Context of Molecules
Encoded by the Major Histocompatibility
Complex 129
IV. Response of Tumor Bearing Individuals to Tumor
Antigens 132
V. Tumor Associated Peptides as Candidate Targets for
Tumor Specific T Lymphocytes 133
VI. Immunotherapeutic Strategies for the Treatment of
Cancer 135
VII. Conclusions 138
References 138
PART
Ha
VACCINE STRATEGIES
8. Development of Epitope Specific
Immunotherapies for Human Malignancies
and Premalignant Lesions Expressing
Mutated ras Genes
SCOTT I. ABRAMS
I. Introduction 145
II. Cellular Immune Response and Antigen
Recognition 146
III. Pathways of Antigen Processing, Presentation,
and Epitope Expression 146
IV. T Lymphocyte Subsets 147
V. ras Oncogenes in Neoplastic Development 147
VI. Cellular Immune Responses Induced by ras Oncogene
Peptides 149
VII. Identification of Mutant ras CD4+ and CD8+ T Cell
Epitopes Reflecting Codon 12 Mutations 149
VIII. Anti raw Immune System Interactions: Implications for
Tumor Immunity and Tumor Escape 156
IX. Paradigm for Anti raw Immune System Interactions in
Cancer Immunotherapy 158
X. Future Directions 159
References 160
part fib
DENDRITIC CELL BASED
GENE THERAPY
9. Introduction to Dendritic Cells
PATRICK BLANCO, A. KAROLINA PALUCKA,
AND JACQUES BANCHEREAU
I. Introduction 167
II. Features of Dendritic Cells 167
III. Dendritic Cell Subsets 169
IV. Functional Heterogeneity of Dendritic Cell
Subsets 171
V. Dendritic Cells in Tumor Immunology 172
VI. Dendritic Cells and Gene Therapy 173
VII. Conclusions 174
References 174
10. DNA and Dendritic Cell Based Genetic
Immunization Against Cancer
LISA H. BUTTERFIELD, ANTONI RIBAS,
AND JAMES S. ECONOMOU
I. Introduction 179
II. Background 179
III. Recent Advances: Methods of Genetic
Immunization 183
IV. Preclinical Development and Translation to the
Clinic 190
V. Proposed and Current Clinical Trials 190
VI. Future Directions 191
References 191
11. RNA Transfected Dendritic Cells
as Immunogens
MICHAEL A. MORSE, SMITA K. NAIR, AND H. KIM LYERLY
I. Introduction 199
II. Advantages of Loading Dendritic Cells with Genetic
Material 199
III. Viral Versus Nonviral Methods of Gene Transfer 200
IV. RNA Versus DNA Loading of Dendritic Cells 200
V. RNA Loading of Dendritic Cells 201
VI Amplification of RNA Used to Load Dendritic
Cells 201
VII. Uses of RNA Loaded Dendritic Cells 201
VIII. Future Directions 202
References 202
PART He
CYTOKINES AND CO FACTORS
12. In Situ Immune Modulation Using
Recombinant Vaccinia Virus Vectors:
Preclinical Studies to Clinical
Implementation
EDMUND C. LATTIME, LAURENCE C. EISENLOHR, LEONARD
G. GOMELLA. AND MICHAEL J. MASTRANGELO
I. Introduction 207
II. Generation of Cell Mediated Immune Responses 208
III. Cytokine Gene Transfer Studies in Antitumor
Immunity 210
IV. In Situ Cytokine Gene Transfer to Enhance Antitumor
Immunity 210
V. Future Directions 215
VI. Conclusions 218
References 219
13. The Use of Particle Mediated Gene
Transfer for Immunotherapy of Cancer
MARK R. ALBERT1NI, DAVID M. KING, AND
ALEXANDER L. RAKHMILEVICH
I. Introduction 225
II. Background 225
III. Recent Advances 228
IV. Issues Regarding Evaluation in Clinical Trials 234
V. Recent Clinical Trials 234
VI. Potential Novel Uses and Future Directions 235
References 235
PART
fid
GENETICALLY MODIFIED EFFECTOR
CELLS FOR IMMUNE BASED
IMMUNOTHERAPY
14. Applications of Gene Transfer in the
Adoptive Immunotherapy of Cancer
KEVIN T. McDONAGH AND ALFRED E. CHANG
I. Introduction 241
II. Use of Gene Modified Tumors to Generate Antitumor
Reactive T Cells 242
III. Genetic Manipulation of T Cells to Enhance Antitumor
Reactivity 246
IV. Genetic Modulation of Dendritic Cells 250
V. Summary 251
References 251
15. Update on the Use of Genetically
Modified Hematopoietic Stem Cells
for Cancer Therapy
EDSEL U. KIM, LEE G. WILKE, AND )AMES |. MULE
I. Introduction 257
II. Human Hematopoietic Stem Cells as Vehicles of Gene
Transfer 258
III. Preclinical Studies of Gene Transfer into Hematopoietic
Stem Cells 259
IV. Applications of Genetically Manipulated
Hematopoietic Stem Cells to the Therapy
of Human Cancer 262
V. Conclusions 268
References 268
PART
fii
ONCOGENE TARGETED
GENE THERAPY
16. Clinical Applications of
Tumor Suppressor Gene Therapy
RAYMOND D. MENG AND WAFIK S. EL DEIRY
I. Introduction 273
II. p53 273
III. BRCA1 275
IV. Onyx 015 Adenoviruses 275
V. Summary and Future Work 276
References 277
17. Cancer Gene Therapy with Tumor
Suppressor Genes Involved
in Cell Cycle Control
RAYMOND D. MENG AND WAFIK S. EL DEIRY
I. Introduction 279
II. p2 mFI/apl 280
III. pl6/iW4 284
IV. Rb 285
V. pl4ARF 286
VI. p27KiP 286
VII. E2F 1 287
VIII. PTEN 288
IX. BRCA1 288
X. VHL 289
XI. FHIT 289
XII. Apoptosis Inducing Genes 289
XIII. Conclusions 291
References 291
18. Cancer Gene Therapy with the p53
Tumor Suppressor Gene
RAYMOND D. MENG AND WAFIK S. EL DEIRY
I. Introduction 299
II. Vectors for Gene Therapy 300
III. p53 302
IV. Conclusions 308
References 308
19. Antisense Downregulation of the
Apoptosis Related Bcl 2 and Bcl xl
Proteins: A New Approach
to Cancer Therapy
IR1NA V. LEBEDEVA AND C.A. STEIN
I. The Bel Family of Proteins and their Role
in Apoptosis 315
II. Downregulation of Bcl 2 Expression: Antisense
Strategies 316
References 324
20. Gene Therapy for Chronic
Myelogenous Leukemia
CATHERINE M. VERFA1LLIE AND
ROBERT CH ZHAO
I. Molecular Mechanisms Underlying Ph+
Leukemias 331
II. Therapy 331
III. Gene Disruption Methods 332
IV. Anti bcr abl Targeted Therapies 332
V. Anti bcr abl Drug Resistance Gene Therapy
for CML 332
VI. Conclusion 334
References 334
PART
iv
MANIPULATION OF DRUG
RESISTANCE MECHANISMS BY
GENE THERAPY
21. Transfer of Drug Resistance Genes into
Hematopoietic Progenitors
OMER N. KOC, STEVEN P. ZIELSKE,
|UST1N C. ROTH, JANE S. REESE, AND
STANTON L. GERSON
I. Introduction 341
II. Rationale for Drug Resistance
Gene Therapy 342
III. Methyltransferase Mediated
Drug Resistance 344
IV. Cytidine Deaminase 348
V. Glutathione S Transferase 348
VI. Dual Drug Resistance Approach 349
VII. Clinical Trials 350
VIII. Conclusion 351
References 351
22. Multidrug Resistance Gene
Therapy in Hematopoietic Cell
Transplantation
RAFAT ABONOUR, JAMES M. CROOP,
AND KENNETH CORNETTA
I. Introduction 355
II. P Glycoprotein 356
III. Targeting Hematopoietic Progenitor Cells for Genetic
Modification 356
IV. Expression of P Glycoprotein in Murine
Hematopoietic Progenitors 357
V. Expression of P Glycoprotein in Human
Hematopoietic Progenitors 358
VI. Results of Early Phase I Studies Using
MDR1 Transduced Hematopoietic
Cells 359
VII. Overcoming Transduction Inefficiency 360
VIII. MDR1 Gene Transfer into Humans: Recent
Progress 361
IX. Implication and Future of MDR1 Gene Therapy in
Humans 361
References 362
23. Development and Application of an
Engineered Dihydrofolate Reductase
and Cytidine Deaminase Based Fusion
Genes in Myeloprotection Based
Gene Therapy Strategies
OWEN A. O CONNOR, TULIN BUDAK ALPDOGAN, AND
JOSEPH R. BERTINO
I. Introduction 365
II. Fusion Genes 368
III. Development of Clinically Applicable Gene Transfer
Approaches 370
IV. Preclinical Evidence for Myeloprotection
Strategies 371
V. Clinical Applications of Myeloprotection
Strategies 373
VI. Challenges 377
References 378
24. Protection from Antifolate Toxicity by
Expression of Drug Resistant
Dihydrofolate Reductase
R. SCOTT McIVOR
I. Introduction 383
II. Drug Resistant Dihydrofolate Reductases 384
III. Protection from Antifolate Toxicity In Vitro 385
IV. Protection from Antifolate Toxicity In Vivo: Retroviral
Transduction Studies 386
V. Dihydrofolate Reductase Transgenic Mouse System
for In Vivo Drug Resistance Studies 386
VI. Antitumor Studies in Animals Expressing
Drug Resistant Dihydrofolate Reductase 387
VII. Antifolate Mediated In Vivo Selection of
Hematopoietic Cells Expressing Drug Resistant
Dihydrofolate Reductase 388
VIII. Summary and Future Considerations 388
References 389
25. A Genomic Approach to the Treatment
of Breast Cancer
K.V. CHIN, DEBORAH TOPPMEYER, THOMAS KEARNEY,
MICHAEL REISS, EDMUND C. LATTIME, AND WILLIAM N. HAIT
I. Introduction 393
II. Toward a Genomic Approach to Therapy 393
III. The Use of DNA Microarrays to Understand Drug
Resistance 396
IV. Effects of Genomic Based Approaches on the
Management of Breast Cancer Patients 398
References 399
part V
ANTI ANIOGENESIS
AND PRO APOPTOTIC
GENE THERAPY
26. Antiangiogenic Gene Therapy
STEVEN K. LIBUTTI AND ANDREW L. FELDMAN
I. Introduction 405
II. Angiogenesis and its Role in Tumor
Biology 405
III. Antiangiogenic Therapy of Cancer and the
Role of Gene Therapy 406
IV. Preclinical Models of Antiangiogenic Gene
Therapy 407
V. Inhibiting Proangiogenic Cytokines 412
VI. Endothelial Cell Specific Gene Delivery 414
VII. Future Directions in Antiangiogenic Gene
Therapy 415
References 415
27. VEGF Targeted Antiangiogenic
Gene Therapy
CALVIN ). KUO, FIL1P A. FARNEBO, CHRISTIAN M. BECKER,
AND JUDAH FOLKMAN
I. Introduction 421
II. Angiogenesis and Tumor Growth 422
III. Gene Therapy for Delivery of Antiangiogenic
Factors 422
IV. Antiangiogenic Gene Therapy in the Experimental and
Clinical Settings 423
V. Vascular Endothelial Growth Factor and
Receptors 423
VI. Vascular Endothelial Growth Factor and
Angiogenesis 424
VII. Vascular Endothelial Growth Factor Inhibition by Gene
Transfer 425
VIII. Issues Regarding Clinical Translation of
Antiangiogenic Gene Therapy 428
IX. Conclusion 432
References 432
28. Strategies for Combining Gene
Therapy with Ionizing Radiation
to Improve Antitumor Efficacy
DAVID H. GORSKI, HELENA ). MAUCERI,
AND RALPH R. WEICHSELBAUM
I. Introduction 435
II. Strategies Using Gene Therapy to Increase the Efficacy
of Radiation Therapy 436
III. Enhancing the Replicative Potential of Antitumor
Viruses with Ionizing Radiation 440
IV. Transcriptional Targeting of Gene Therapy with
Ionizing Radiation (Genetic Radiotherapy) 441
V. Summary and Future Directions 443
References 444
29. Virotherapy with Replication Selective
Oncolytic Adenoviruses: A Novel
Therapeutic Platform for Cancer
DAVID KIRN
I. Introduction 449
II. Attributes of Replication Selective Adenoviruses for
Cancer Treatment 451
III. Biology of Human Adenovirus 451
IV. Mechanisms of Adenovirus Mediated Cell
Killing 451
V. Approaches to Optimizing Tumor Selective
Adenovirus Replication 452
VI. Background: dl 1520 (ONYX 015) 452
VII. Clinical Trial Results with Wild Type Adenovirus:
Flawed Study Design 453
VIII. A Novel Staged Approach to Clinical Research
with Replication Selective Viruses: #152O
(ONYX 015) 454
IX. Results from Clinical Trials with dll520
(ONYX 015) 455
X. Results from Clinical Trials with dll520 (ONYX 015):
Summary 459
XL Future Directions 460
XII. Summary 462
References 462
30. El A Cancer Gene Therapy
DUEN HWA YAN, RUPING SHAO, AND MIEN CHIE HUNG
I. Introduction 465
II. HER2 Overexpression and E1 A Mediated Antitumor
Activity 465
III. Mechanisms of El A Mediated Anti Tumor
Activity 467
IV. El A Gene Therapy: Preclinical Models 470
V. El A Gene Therapy: Clinical Trials 472
VI. Conclusion 473
References 473
PART
VI
PRODRUG ACTIVATION
STRATEGIES FOR GENE THERAPY
OF CANCER
31. Preemptive and Therapeutic Uses of
Suicide Genes for Cancer
and Leukemia
FREDERICK L. MOOLTEN AND PAULA). MROZ
I. Introduction 481
II. Therapeutic Uses of Suicide Genes 482
III. Preemptive Uses of Suicide Genes in Cancer 483
IV. Creation of Stable Suicide Functions by Combining
Suicide Gene Transduction with Endogenous Gene
Loss 485
V. Preemptive Uses of Suicide Genes to Control
Graft Versus Host Disease in Leukemia 487
VI. Future Prospects for Preemptive Use of Suicide
Genes 488
References 489
32. Treatment of Mesothelioma Using
Adenoviral Mediated Delivery of Herpes
Simplex Virus Thymidine Kinase Gene in
Combination with Ganciclovir
DANIEL H. STERMAN AND STEVEN M. ALBELDA
I. Introduction 493
II. Clinical Use of HS V TK in the Treatment of Localized
Malignancies 494
III. Challenges and Future Directions 499
References 501
33. The Use of Suicide Gene Therapy
for the Treatment of Malignancies
of the Brain
KEVIN D. JUDY AND STEPHEN L. ECK
I. Introduction 505
II. Retrovirus Vector for HSV TK 506
III. Adenovirus Vector for HSV TK 509
IV. Herpes Simplex Virus Vectors Expressing Endogenous
HSV TK 510
V. Promising Preclinical Studies 510
References 511
34. Case Study of Combined
Gene and Radiation Therapy as
an Approach in the Treatment
of Cancer
BIN S. TEH, MARIA T. VLACHAKI, LAURA K. AGUILAR,
BRIAN MILES, GUSTAVO AYALA, DOV KADMON,
THOMAS WHEELER, TIMOTHY C. THOMPSON,
E. BRIAN BUTLER, AND ESTUARDO AGUILAR CORDOVA
I. Introduction 513
II. Background of the Field 514
III. Recent Advances in Herpes Simplex Virus Thymidine
Kinase Suicide Gene Therapy 515
IV. Combined Herpes Simplex Virus Thymidine
Kinase Suicide Gene Therapy and
Radiotherapy 516
V. Issues Regarding Clinical Trials, Translation
into Clinical Use, Preclinical Development,
Efficacy, Endpoints, and Gene
Expression 521
VI. Potential Novel Uses and Future
Directions 522
References 523
Index 525
|
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV014485114 |
| callnumber-first | R - Medicine |
| callnumber-label | RC271 |
| callnumber-raw | RC271.G45 |
| callnumber-search | RC271.G45 |
| callnumber-sort | RC 3271 G45 |
| callnumber-subject | RC - Internal Medicine |
| classification_rvk | XH 3500 |
| ctrlnum | (OCoLC)49664744 (DE-599)BVBBV014485114 |
| dewey-full | 616.99/4042 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.99/4042 |
| dewey-search | 616.99/4042 |
| dewey-sort | 3616.99 44042 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| edition | 2. ed. |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01999nam a2200541zc 4500</leader><controlfield tag="001">BV014485114</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20030703 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">020603s2002 xxuad|| |||| 00||| eng d</controlfield><datafield tag="010" ind1=" " ind2=" "><subfield code="a">2001099437</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0124375510</subfield><subfield code="9">0-12-437551-0</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)49664744</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV014485114</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">xxu</subfield><subfield code="c">US</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC271.G45</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.99/4042</subfield><subfield code="2">21</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XH 3500</subfield><subfield code="0">(DE-625)152892:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Gene therapy of cancer</subfield><subfield code="b">translational approaches from preclinical studies to clinical implementation</subfield><subfield code="c">ed. by Edmund C. Lattime ...</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">2. ed.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">San Diego [u.a.]</subfield><subfield code="b">Acad. Press</subfield><subfield code="c">2002</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XIX, 534 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer - Immunothérapie</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer - Thérapie génique</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer</subfield><subfield code="x">Gene therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer</subfield><subfield code="x">Immunotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gene Therapy</subfield><subfield code="x">methods</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunotherapy</subfield><subfield code="x">methods</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoplasms</subfield><subfield code="x">genetics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoplasms</subfield><subfield code="x">therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Protein Biosynthesis</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Gentherapie</subfield><subfield code="0">(DE-588)4296957-8</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Gentherapie</subfield><subfield code="0">(DE-588)4296957-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lattime, Edmund C.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gerson, Stanton L.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=009879472&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-009879472</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV014485114 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T19:03:01Z |
| institution | BVB |
| isbn | 0124375510 |
| language | English |
| lccn | 2001099437 |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-009879472 |
| oclc_num | 49664744 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | XIX, 534 S. Ill., graph. Darst. |
| publishDate | 2002 |
| publishDateSearch | 2002 |
| publishDateSort | 2002 |
| publisher | Acad. Press |
| record_format | marc |
| spelling | Gene therapy of cancer translational approaches from preclinical studies to clinical implementation ed. by Edmund C. Lattime ... 2. ed. San Diego [u.a.] Acad. Press 2002 XIX, 534 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Includes bibliographical references and index Cancer - Immunothérapie Cancer - Thérapie génique Cancer Gene therapy Cancer Immunotherapy Gene Therapy methods Immunotherapy methods Neoplasms genetics Neoplasms therapy Protein Biosynthesis Krebs Medizin (DE-588)4073781-0 gnd rswk-swf Gentherapie (DE-588)4296957-8 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Krebs Medizin (DE-588)4073781-0 s Gentherapie (DE-588)4296957-8 s DE-604 Lattime, Edmund C. Sonstige oth Gerson, Stanton L. Sonstige oth HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=009879472&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Gene therapy of cancer translational approaches from preclinical studies to clinical implementation Cancer - Immunothérapie Cancer - Thérapie génique Cancer Gene therapy Cancer Immunotherapy Gene Therapy methods Immunotherapy methods Neoplasms genetics Neoplasms therapy Protein Biosynthesis Krebs Medizin (DE-588)4073781-0 gnd Gentherapie (DE-588)4296957-8 gnd |
| subject_GND | (DE-588)4073781-0 (DE-588)4296957-8 (DE-588)4143413-4 |
| title | Gene therapy of cancer translational approaches from preclinical studies to clinical implementation |
| title_auth | Gene therapy of cancer translational approaches from preclinical studies to clinical implementation |
| title_exact_search | Gene therapy of cancer translational approaches from preclinical studies to clinical implementation |
| title_full | Gene therapy of cancer translational approaches from preclinical studies to clinical implementation ed. by Edmund C. Lattime ... |
| title_fullStr | Gene therapy of cancer translational approaches from preclinical studies to clinical implementation ed. by Edmund C. Lattime ... |
| title_full_unstemmed | Gene therapy of cancer translational approaches from preclinical studies to clinical implementation ed. by Edmund C. Lattime ... |
| title_short | Gene therapy of cancer |
| title_sort | gene therapy of cancer translational approaches from preclinical studies to clinical implementation |
| title_sub | translational approaches from preclinical studies to clinical implementation |
| topic | Cancer - Immunothérapie Cancer - Thérapie génique Cancer Gene therapy Cancer Immunotherapy Gene Therapy methods Immunotherapy methods Neoplasms genetics Neoplasms therapy Protein Biosynthesis Krebs Medizin (DE-588)4073781-0 gnd Gentherapie (DE-588)4296957-8 gnd |
| topic_facet | Cancer - Immunothérapie Cancer - Thérapie génique Cancer Gene therapy Cancer Immunotherapy Gene Therapy methods Immunotherapy methods Neoplasms genetics Neoplasms therapy Protein Biosynthesis Krebs Medizin Gentherapie Aufsatzsammlung |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=009879472&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT lattimeedmundc genetherapyofcancertranslationalapproachesfrompreclinicalstudiestoclinicalimplementation AT gersonstantonl genetherapyofcancertranslationalapproachesfrompreclinicalstudiestoclinicalimplementation |